About Brinda Balakrishnan

Corporate strategist and deal maker merging business acumen with a physician-scientist perspective, focusing on value creation and risk stratification to advance impactful medicines for patients.

• Accountable for inorganic growth strategy leading to growing R&D portfolio
• Responsible for transactions (M&A, licensing, research collaborations) ranging from preclinical through commercial stage assets across multiple modalities (gene therapy, oligonucleotides, biologics, small molecules)
• Experienced with sell side transactions (licensing, asset sale) for preclinical, clinical and commercial assets
• Supported and co-led private financing activities resulting in non-dilutive and venture financing
• Engaging regularly with Board of Directors on corporate strategy and business development transactions